Welcome
Innovative Vaccine Solutions Replicating Real World Natural Immunity
Malaika Vx is developing novel, transformative and universal vaccines for HIV and other viral infectious diseases.
Malaika Vx is developing novel, transformative and universal vaccines for HIV and other viral infectious diseases.
Our vaccine technology combines advances in antigen identification (what to 'target' for an effective immune response) with next generation vaccine delivery systems, including recombinant Vesicular Stomatitis Virus (rVSV) viral vector delivery platform and targeted lipid nanoparticles.
This effort involved numerous domestic and international funders, including the National Institute of Health, the Bill and Melinda Gates Foundation, Canadian Institute of Health Research, and the National Microbiology Lab (NML), Public Health Agency of Canada (PHAC).
Our research and development pipeline spans RNA and DNA viruses, learning from natural immunity to viral infectious diseases. It represents a blend of cutting-edge science and public health necessity, addressing both well-known and emerging viral threats.
Malaika Vx is dedicated to providing innovative, effective solutions that can lead to the prevention, treatment, and eventual eradication of these viruses, improving health outcomes across the globe and especially for those most in need.
Malaika Vx has built its scientific capacities and capabilities through strategic partnerships and contractual agreements with leading scientific and vaccine development entities. Our collaborations ensure that our solutions are at the forefront of vaccine development and impactful, targeting those most in need. It has a world class scientific advisory board (SAB). This board and our development process is managed by a lean and experienced management team.
Our proprietary antigen platform allows for the precise identification and selection of antigens that can elicit strong and effective immune response, generating both potent T cell and antibody response for both RNA and DNA viruses. It induces minimal inflammation, has broad coverage in the human population, and the opportunity for viral escape is limited.
Based on the development of rVSV-ZEBOV, licenced by Merck (ERVEBO®), our recombinant vesicular stomatitis virus vaccine delivery platform represents a new cutting-edge tool in vaccine and therapeutic development, with its combination of enhanced safety, efficacy, and versatility. It maintains high replicative capability ensuring efficient payload expression.
Our next-generation mRNA-LNP loaded technology is designed to boost antigen presentation by dendritic cells, promoting effective cellular immunity. Our formulation delivering a small payload, ensures long-term stability and compatibility with cold-chain storage/transport, widening accessibility of mRNA LNP vaccine in low-income countries.
Copyright © 2024 Malaika website - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.